entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 21:34:08 - browse：59366

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Millions may soon lose Medicaid when they don't have to

hotspot

WSS

The thinking behind the controversial eating disorder chatbot Tessa

Cholera vaccine supplies dangerously low, outbreaks surging

Eli Lilly’s Mounjaro succeeds in second weight

Novo pauses ads for weight loss drug Wegovy amid demand

Readout Newsletter: Beam, Prozac, "TechBio" and more

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In age of alternative facts, a scholarly course on calling out crap

Can medical device makers keep up in the race to treat obesity?

In Memoriam: Notable people who died in 2023

Are embryos people? Reproductive medicine's future depends on the answer

Apple is now the first public company to be valued at $3 trillion

NEJM study measures Covid brain fog, impact on IQ

Bright Health sells Medicare Advantage business to Molina

FDA approves first new drug developed for postpartum depression

Activists slam private health insurers over coverage restrictions

Pfizer is about to make a big push in cancer. Will investors listen?

knowledge

Childhood vaccination ad campaign launches in the U.K.

Change Healthcare cyberattack shows risk of industry consolidation

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Children’s Hospital revives plan for pedestrian bridge

Medicare Advantage isn’t working — for anyone

Laying a path for careers in science

knowledge

hotspot

hotspot

focus